Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against the chikungunya virus and Lyme disease.

Valneva at a glance

Commercial vaccines


Total revenues in 2022

Unique vaccine development programs


differentiated clinical and pre-clinical assets

robust commercial portfolio


on prevention of infectious diseases with significant unmet medical need


employees in six countries